<ul>
<li>分析師對這些鮮為人知的生物製藥股票讚不絕口</li>
</ul>
<p>Kymera Therapeutics, Inc. (NASDAQ:KYMR - 免費報告) - Leerink Partners 的投資分析師在 8 月 11 日星期一向投資者發佈了對 Kymera Therapeutics 第三季度 2026 年的收益預期。Leerink Partners 分析師 F. Khurshid 預計該公司本季度每股收益為（$1.09）。Kymera Therapeutics 當前全年的共識收益預期為每股（$2.79）。Leerink Partners 還發布了對 Kymera Therapeutics 第四季度 2026 年收益的預期為每股（$1.11）。</p>
<p>其他一些券商最近也對 KYMR 發表了評論。Oppenheimer 在 6 月 27 日星期五的研究報告中重申了 “跑贏大盤” 的評級，並將 Kymera Therapeutics 的目標價下調至 $53.00（之前為 $56.00）。Jefferies Financial Group 在 6 月 25 日星期三的研究報告中對 Kymera Therapeutics 的股票設定了 $64.00 的目標價，並給予該股票 “買入” 評級。高盛集團在 7 月 15 日星期二的研究報告中將 Kymera Therapeutics 的股票評級提升至 “強力買入”。摩根士丹利在 7 月 3 日星期四的研究報告中開始覆蓋 Kymera Therapeutics 的股票。他們為該公司設定了 “增持” 評級和 $70.00 的目標價。最後，富國銀行在 6 月 26 日星期四的研究報告中將 Kymera Therapeutics 的目標價從 $57.00 下調至 $53.00，併為該公司設定了 “增持” 評級。兩位投資分析師對該股票給予了持有評級，十六位給予了買入評級，三位給予了強力買入評級。根據 MarketBeat.com 的數據，該股票目前的平均評級為 “買入”，平均目標價為 $59.11。</p>
<p>獲取 <strong>Kymera Therapeutics</strong> 的提醒：</p>
<p><strong>獲取我們對 Kymera Therapeutics 的最新股票分析</strong></p>
<h2>Kymera Therapeutics 股票上漲 5.4%</h2>
<p>NASDAQ:KYMR 的股票在星期三開盤價為 $39.71。Kymera Therapeutics 的 52 周低點為 $19.44，52 周高點為 $53.27。該股票的市值為 $25.9 億，市盈率為 -11.54，貝塔值為 2.18。該公司的 50 日簡單移動平均線為 $44.93，200 日簡單移動平均線為 $36.45。</p>
<p>Kymera Therapeutics (NASDAQ:KYMR - 獲取免費報告) 最近在 8 月 11 日星期一宣佈了其季度收益結果。該公司報告本季度每股收益為（$0.95），低於分析師的共識預期（$0.83）$0.12。該公司在本季度的收入為 $1148 萬，而共識預期為 $1737 萬。Kymera Therapeutics 的淨利潤率為 -616.03%，股本回報率為 -32.86%。該公司的收入同比下降了 55.1%。在去年同期，該公司每股收益為（$0.58）。</p>
<h2>Kymera Therapeutics 的內部買賣</h2>
<p>在其他 Kymera Therapeutics 的新聞中，董事 Jeffrey W. Albers 在 6 月 3 日星期二出售了 6,349 股公司的股票。股票以平均價格 $49.00 出售，總交易額為 $311,101.00。該交易在向 SEC 提交的文件中披露，文件可在此鏈接查看。此外，董事 Bvf Partners L. P/Il 在 6 月 30 日星期一購買了 317,167 股公司的股票。股票以每股平均價格 $44.00 購買，總交易額為 $13,955,348.00。購買後，該董事直接持有公司 2,798,795 股，價值 $123,146,980。這代表其持股比例增加了 12.78%。該購買的披露信息可以在這裏找到。在過去三個月中，內部人士共出售了價值 $2,334,301 的 48,349 股公司股票。公司內部人士持有該股票的 16.01%。</p>
<h2>機構資金流入和流出</h2>
<p>對該股票的對沖基金最近進行了買賣。Franklin Resources Inc. 在第四季度將其在 Kymera Therapeutics 的股份增加了 30.3%。Franklin Resources Inc. 目前擁有 38,367 股公司股票，價值 $1,544,000，此前在該期間內又增持了 8,927 股。Geode Capital Management LLC 在第四季度將其在 Kymera Therapeutics 的股份增加了 5.0%。Geode Capital Management LLC 目前擁有 1,105,487 股公司股票，價值 $44,484,000，此前在該期間內又增持了 52,263 股。富國銀行 MN 在第四季度將其在 Kymera Therapeutics 的股份增加了 51.8%。富國銀行 MN 目前擁有 21,939 股公司股票，價值 $883,000，此前在該期間內又增持了 7,487 股。Summit Investment Advisors Inc. 在第四季度將其在 Kymera Therapeutics 的股份增加了 9.0%。Summit Investment Advisors Inc. 目前擁有 4,912 股公司股票，價值 $198,000，此前在該期間內又增持了 406 股。最後，Affinity Asset Advisors LLC 在第四季度獲得了 Kymera Therapeutics 的新股份，價值 $1,609,000。</p>
<h2>Kymera Therapeutics 公司簡介</h2>
<p>（獲取免費報告）</p>
<p>Kymera Therapeutics, Inc. 是一家生物製藥公司，專注於發現和開發新型小分子治療藥物，通過利用身體自身的自然蛋白質降解系統選擇性降解致病蛋白。它正在開發 IRAK4 項目，該項目正在進行 II 期臨牀試驗，治療免疫學 - 炎症疾病，包括膿皰性汗腺炎、特應性皮炎；STAT3 項目用於治療血液惡性腫瘤和實體腫瘤，以及自身免疫疾病和纖維化；MDM2 項目用於治療血液惡性腫瘤和實體腫瘤。</p>
<h2>瞭解更多</h2>
<ul>
<li>我們更看好的五隻股票，而不是 Kymera Therapeutics</li>
<li>如何開始投資房地產</li>
<li>數據中心需求旺盛——這隻 REIT 擁有整個投資組合</li>
<li>股票平均計算器</li>
<li>3 只電池股票，適合買入並持有到本十年結束</li>
<li>日經 225 指數是什麼？</li>
<li>在能源市場緊張局勢加劇時值得考慮的 3 只股票</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9S1lNUg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9S1lNUg"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。請將任何問題或意見發送至 contact@marketbeat.com.</em></p>
<h2>你現在應該投資 1,000 美元在 Kymera Therapeutics 嗎？</h2>
<p>在考慮 Kymera Therapeutics 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 Kymera Therapeutics 並不在名單上。</p>
<p>雖然 Kymera Therapeutics 目前在分析師中獲得了買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

KYMR

<p>Leerink Partners 的投資分析師發佈了 Kymera Therapeutics 2026 年第三季度的收益預估，預測每股收益為（$1.09）。全年共識為每股（$2.79）。其他券商提供了不同的評級和價格目標，平均目標價為$59.11。Kymera 的股票上漲了 5.4%，目前價格為$39.71，市值為 25.9 億美元。該公司報告上個季度每股收益虧損（$0.95），未達到預期，收入同比下降了 55.1%</p>

<ul>
<li>Analysts Can't Get Enough of These Little-Known Biopharma Stocks</li>
</ul>
<div class="lb-trans"><ul>
<li>分析師對這些鮮為人知的生物製藥股票讚不絕口</li>
</ul>
</div><p>Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) - Investment analysts at Leerink Partnrs issued their Q3 2026 earnings estimates for shares of Kymera Therapeutics in a note issued to investors on Monday, August 11th. Leerink Partnrs analyst F. Khurshid expects that the company will post earnings per share of ($1.09) for the quarter. The consensus estimate for Kymera Therapeutics' current full-year earnings is ($2.79) per share. Leerink Partnrs also issued estimates for Kymera Therapeutics' Q4 2026 earnings at ($1.11) EPS.</p>
<div class="lb-trans"><p>Kymera Therapeutics, Inc. (NASDAQ:KYMR - 免費報告) - Leerink Partners 的投資分析師在 8 月 11 日星期一向投資者發佈了對 Kymera Therapeutics 第三季度 2026 年的收益預期。Leerink Partners 分析師 F. Khurshid 預計該公司本季度每股收益為（$1.09）。Kymera Therapeutics 當前全年的共識收益預期為每股（$2.79）。Leerink Partners 還發布了對 Kymera Therapeutics 第四季度 2026 年收益的預期為每股（$1.11）。</p>
</div><p>A number of other brokerages have also recently commented on KYMR. Oppenheimer reissued an &#34;outperform&#34; rating and issued a $53.00 price objective (down from $56.00) on shares of Kymera Therapeutics in a research note on Friday, June 27th. Jefferies Financial Group set a $64.00 price target on shares of Kymera Therapeutics and gave the stock a &#34;buy&#34; rating in a research note on Wednesday, June 25th. The Goldman Sachs Group raised shares of Kymera Therapeutics to a &#34;strong-buy&#34; rating in a research note on Tuesday, July 15th. Morgan Stanley initiated coverage on shares of Kymera Therapeutics in a research note on Thursday, July 3rd. They set an &#34;overweight&#34; rating and a $70.00 price target for the company. Finally, Wells Fargo &amp; Company dropped their price target on shares of Kymera Therapeutics from $57.00 to $53.00 and set an &#34;overweight&#34; rating for the company in a research note on Thursday, June 26th. Two investment analysts have rated the stock with a hold rating, sixteen have given a buy rating and three have given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of &#34;Buy&#34; and an average target price of $59.11.</p>
<div class="lb-trans"><p>其他一些券商最近也對 KYMR 發表了評論。Oppenheimer 在 6 月 27 日星期五的研究報告中重申了 “跑贏大盤” 的評級，並將 Kymera Therapeutics 的目標價下調至 $53.00（之前為 $56.00）。Jefferies Financial Group 在 6 月 25 日星期三的研究報告中對 Kymera Therapeutics 的股票設定了 $64.00 的目標價，並給予該股票 “買入” 評級。高盛集團在 7 月 15 日星期二的研究報告中將 Kymera Therapeutics 的股票評級提升至 “強力買入”。摩根士丹利在 7 月 3 日星期四的研究報告中開始覆蓋 Kymera Therapeutics 的股票。他們為該公司設定了 “增持” 評級和 $70.00 的目標價。最後，富國銀行在 6 月 26 日星期四的研究報告中將 Kymera Therapeutics 的目標價從 $57.00 下調至 $53.00，併為該公司設定了 “增持” 評級。兩位投資分析師對該股票給予了持有評級，十六位給予了買入評級，三位給予了強力買入評級。根據 MarketBeat.com 的數據，該股票目前的平均評級為 “買入”，平均目標價為 $59.11。</p>
</div><p>Get <strong>Kymera Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Kymera Therapeutics</strong> 的提醒：</p>
</div><p><strong>Get Our Latest Stock Analysis on Kymera Therapeutics</strong></p>
<div class="lb-trans"><p><strong>獲取我們對 Kymera Therapeutics 的最新股票分析</strong></p>
</div><h2>Kymera Therapeutics Stock Up 5.4%</h2>
<div class="lb-trans"><h2>Kymera Therapeutics 股票上漲 5.4%</h2>
</div><p>Shares of NASDAQ:KYMR opened at $39.71 on Wednesday. Kymera Therapeutics has a 52 week low of $19.44 and a 52 week high of $53.27. The stock has a market capitalization of $2.59 billion, a P/E ratio of -11.54 and a beta of 2.18. The firm has a fifty day simple moving average of $44.93 and a two-hundred day simple moving average of $36.45.</p>
<div class="lb-trans"><p>NASDAQ:KYMR 的股票在星期三開盤價為 $39.71。Kymera Therapeutics 的 52 周低點為 $19.44，52 周高點為 $53.27。該股票的市值為 $25.9 億，市盈率為 -11.54，貝塔值為 2.18。該公司的 50 日簡單移動平均線為 $44.93，200 日簡單移動平均線為 $36.45。</p>
</div><p>Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last announced its quarterly earnings results on Monday, August 11th. The company reported ($0.95) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.83) by ($0.12). The company had revenue of $11.48 million during the quarter, compared to the consensus estimate of $17.37 million. Kymera Therapeutics had a negative net margin of 616.03% and a negative return on equity of 32.86%. The business's revenue was down 55.1% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.58) earnings per share.</p>
<div class="lb-trans"><p>Kymera Therapeutics (NASDAQ:KYMR - 獲取免費報告) 最近在 8 月 11 日星期一宣佈了其季度收益結果。該公司報告本季度每股收益為（$0.95），低於分析師的共識預期（$0.83）$0.12。該公司在本季度的收入為 $1148 萬，而共識預期為 $1737 萬。Kymera Therapeutics 的淨利潤率為 -616.03%，股本回報率為 -32.86%。該公司的收入同比下降了 55.1%。在去年同期，該公司每股收益為（$0.58）。</p>
</div><h2>Insider Buying and Selling at Kymera Therapeutics</h2>
<div class="lb-trans"><h2>Kymera Therapeutics 的內部買賣</h2>
</div><p>In other Kymera Therapeutics news, Director Jeffrey W. Albers sold 6,349 shares of the company's stock in a transaction that occurred on Tuesday, June 3rd. The shares were sold at an average price of $49.00, for a total transaction of $311,101.00. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Bvf Partners L. P/Il purchased 317,167 shares of the business's stock in a transaction on Monday, June 30th. The shares were bought at an average price of $44.00 per share, for a total transaction of $13,955,348.00. Following the purchase, the director directly owned 2,798,795 shares in the company, valued at $123,146,980. This represents a 12.78% increase in their position. The disclosure for this purchase can be found here. Insiders have sold a total of 48,349 shares of company stock worth $2,334,301 in the last three months. 16.01% of the stock is owned by company insiders.</p>
<div class="lb-trans"><p>在其他 Kymera Therapeutics 的新聞中，董事 Jeffrey W. Albers 在 6 月 3 日星期二出售了 6,349 股公司的股票。股票以平均價格 $49.00 出售，總交易額為 $311,101.00。該交易在向 SEC 提交的文件中披露，文件可在此鏈接查看。此外，董事 Bvf Partners L. P/Il 在 6 月 30 日星期一購買了 317,167 股公司的股票。股票以每股平均價格 $44.00 購買，總交易額為 $13,955,348.00。購買後，該董事直接持有公司 2,798,795 股，價值 $123,146,980。這代表其持股比例增加了 12.78%。該購買的披露信息可以在這裏找到。在過去三個月中，內部人士共出售了價值 $2,334,301 的 48,349 股公司股票。公司內部人士持有該股票的 16.01%。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>機構資金流入和流出</h2>
</div><p>Hedge funds have recently bought and sold shares of the stock. Franklin Resources Inc. increased its stake in shares of Kymera Therapeutics by 30.3% in the fourth quarter. Franklin Resources Inc. now owns 38,367 shares of the company's stock worth $1,544,000 after acquiring an additional 8,927 shares during the period. Geode Capital Management LLC increased its stake in shares of Kymera Therapeutics by 5.0% in the fourth quarter. Geode Capital Management LLC now owns 1,105,487 shares of the company's stock worth $44,484,000 after acquiring an additional 52,263 shares during the period. Wells Fargo &amp; Company MN increased its stake in shares of Kymera Therapeutics by 51.8% in the fourth quarter. Wells Fargo &amp; Company MN now owns 21,939 shares of the company's stock worth $883,000 after acquiring an additional 7,487 shares during the period. Summit Investment Advisors Inc. increased its stake in shares of Kymera Therapeutics by 9.0% in the fourth quarter. Summit Investment Advisors Inc. now owns 4,912 shares of the company's stock worth $198,000 after acquiring an additional 406 shares during the period. Finally, Affinity Asset Advisors LLC acquired a new stake in shares of Kymera Therapeutics in the fourth quarter worth $1,609,000.</p>
<div class="lb-trans"><p>對該股票的對沖基金最近進行了買賣。Franklin Resources Inc. 在第四季度將其在 Kymera Therapeutics 的股份增加了 30.3%。Franklin Resources Inc. 目前擁有 38,367 股公司股票，價值 $1,544,000，此前在該期間內又增持了 8,927 股。Geode Capital Management LLC 在第四季度將其在 Kymera Therapeutics 的股份增加了 5.0%。Geode Capital Management LLC 目前擁有 1,105,487 股公司股票，價值 $44,484,000，此前在該期間內又增持了 52,263 股。富國銀行 MN 在第四季度將其在 Kymera Therapeutics 的股份增加了 51.8%。富國銀行 MN 目前擁有 21,939 股公司股票，價值 $883,000，此前在該期間內又增持了 7,487 股。Summit Investment Advisors Inc. 在第四季度將其在 Kymera Therapeutics 的股份增加了 9.0%。Summit Investment Advisors Inc. 目前擁有 4,912 股公司股票，價值 $198,000，此前在該期間內又增持了 406 股。最後，Affinity Asset Advisors LLC 在第四季度獲得了 Kymera Therapeutics 的新股份，價值 $1,609,000。</p>
</div><h2>Kymera Therapeutics Company Profile</h2>
<div class="lb-trans"><h2>Kymera Therapeutics 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.</p>
<div class="lb-trans"><p>Kymera Therapeutics, Inc. 是一家生物製藥公司，專注於發現和開發新型小分子治療藥物，通過利用身體自身的自然蛋白質降解系統選擇性降解致病蛋白。它正在開發 IRAK4 項目，該項目正在進行 II 期臨牀試驗，治療免疫學 - 炎症疾病，包括膿皰性汗腺炎、特應性皮炎；STAT3 項目用於治療血液惡性腫瘤和實體腫瘤，以及自身免疫疾病和纖維化；MDM2 項目用於治療血液惡性腫瘤和實體腫瘤。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>瞭解更多</h2>
</div><ul>
<li>Five stocks we like better than Kymera Therapeutics</li>
<li>How to Start Investing in Real Estate</li>
<li>Data Centers in Demand—This REIT Owns a Whole Portfolio</li>
<li>Stock Average Calculator</li>
<li>3 Battery Stocks to Buy and Hold for the Rest of the Decade</li>
<li>What is the Nikkei 225 index?</li>
<li>3 Stocks to Consider as Tension Builds in Energy Markets</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票，而不是 Kymera Therapeutics</li>
<li>如何開始投資房地產</li>
<li>數據中心需求旺盛——這隻 REIT 擁有整個投資組合</li>
<li>股票平均計算器</li>
<li>3 只電池股票，適合買入並持有到本十年結束</li>
<li>日經 225 指數是什麼？</li>
<li>在能源市場緊張局勢加劇時值得考慮的 3 只股票</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9S1lNUg" alt="" original-src="https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx?Prefix=NASDAQ&amp;Symbol=KYMR"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。請將任何問題或意見發送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Kymera Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Kymera Therapeutics 嗎？</h2>
</div><p>Before you consider Kymera Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Kymera Therapeutics 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kymera Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 Kymera Therapeutics 並不在名單上。</p>
</div><p>While Kymera Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Kymera Therapeutics 目前在分析師中獲得了買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Leerink Partners 對 Kymera Therapeutics 第三季度收益的預估是什麼？